This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Adverse Events (AEs)
Timeframe: From the time of first dose to 28 days post last dose of ANS02
Incidence of Serious Adverse Events (SAEs)
Timeframe: From time of first dose to 28 days post last dose of ANS02
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Timeframe: From time of first dose of ANS02 to end of DLT period (approximately 28 days)
Incidence of baseline laboratory finding, ECG and vital signs changes
Timeframe: From time of first dose to 28 days post last dose of ANS02
Avistone Clinical Study Information Center